Drug Profile

Research programme: immuno-oncology therapeutics - Palvella Therapeutics/Seagen

Alternative Names: Research programme: antibody-Anticalin fusion proteins - Palvella Therapeutics/Seagen

Latest Information Update: 17 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pieris Pharmaceuticals; Seattle Genetics
Developer Palvella Therapeutics; Seagen
Class Antibodies; Antineoplastics; Immunotherapies; Lipocalins; Recombinant fusion proteins
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics
28 Sep 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
28 Sep 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com